Local, exendin-(939)-insensitive, site of action of GLP-1 in canine ileum

E. E. Daniel1, M. Anvari2, J. E. T. Fox-Threlkeld3, and T. J. McDonald4

Departments of 1 Medicine and 2 Surgery and 3 School of Nursing, McMaster University, Hamilton, Ontario L8N 3Z5; and 4 Department of Medicine, University of Western Ontario, London, Ontario, Canada N6A SA5


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

Glucagon-like peptide-1 (GLP-1) modulates glucose levels following a meal, including by inhibition of gastric emptying and intestinal transport. Intra-arterial injection of GLP-1 into the gastric corpus, antrum, or pylorus of anesthetized dogs had no effect on the contractile activity of the resting or neurally activated stomach. GLP-1 injected intra-arterially inhibited intestinal segments when activated by enteric nerve stimulation but not by acetylcholine. Isolated ileum segments were perfused intra-arterially, instrumented with strain gauges to record circular muscle activity and with subserosal electrodes to stimulate enteric nerves. GLP-1 caused concentration-dependent inhibition of nerve-stimulated phasic but not tonic activity. This was absent during TTX-induced activity and partly prevented by NG-nitro-L-arginine. Exendin-(939), the GLP-1 antagonist, had no intrinsic activity and did not affect the actions of GLP-1. Capsaicin mimicked the effects of GLP-1 and may have reduced the effect of subsequent GLP-1. GLP-1 may mediate paracrine action on afferent nerves in the canine ileal mucosa using an unusual receptor.

gastric emptying; intestinal motility; capsaicin; afferent nerves; paracrine action


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

GLUCAGON-LIKE PEPTIDE (GLP)-1 is produced in L-type endocrine cells of the ileal and colonic mucosa, where it is usually colocalized with peptide YY and GLP-2 (8, 20, 21, 24, 42, 49, 53, 68). It contains sequence similarities with glucagon and is derived by alternate processing of a common precursor, proglucagon (amino acids 78-107). It is released by glucose, fatty, and peptone meals (3, 20, 21, 42, 49), which is constrained by somatostatin (41). GLP-1 acts as an incretin (51, 60, 62) with multiple actions on pancreatic beta -cells: it raises cAMP, inhibits the ATP-sensitive K+ channel, depolarizes, enhances Ca2+ entry, and promotes insulin release (40, 46). It also inhibits release of glucagon from pancreatic alpha -cells, possibly by increasing release of somatostatin by D cells (20, 21, 42, 49). When the action of GLP-1 is inhibited, glucose tolerance is impaired (11). Receptors for GLP-1 are present in the periphery as well as the central nervous system, in which it may act to modulate fluid and food intake (7, 10, 15, 18, 19, 39, 48, 52, 72). GLP-1 receptors are also present on afferent nerves, and several of its actions are postulated to involve activation of vagal afferents or those from the dorsal roots (45, 54, 70).

Until now, most receptors have been characterized by their susceptibility to agonists and antagonists and in several cases by cloning and expression of the receptor in cell lines. Only one cloned GLP-1 receptor has been found (7, 10, 15, 18, 39, 52, 72), but there is one previous case in which receptors have distinctly different pharmacology, i.e., insensitivity to the antagonist exendin-(939), as previously described (54).

GLP-1 has important effects on gastrointestinal motility. It inhibits gastric emptying and intestinal transit (4, 7, 48, 57, 66, 67) and is postulated to be involved in ileal braking of gastric emptying and intestinal transit following glucose (5, 22, 47, 50, 71), fat (37, 38, 59, 61), and peptone (38) meals. The locations of receptors for these actions have not been identified, but they are known to require an intact vagus nerve (36, 44, 70). We demonstrated in awake instrumented dogs that GLP-1 inhibits gastric emptying of a saline meal by decreasing the number and volume of flow pulses through the pylorus. These changes were associated with inhibition of antropyloric pressure waves, stimulation of isolated pyloric pressure waves, and an increase in pyloric tone (4).

The half-life of GLP-1 in the plasma is short (1-2 min) as it is rapidly degraded by dipeptidyl peptidase IV, and it is uncertain whether the active peptide reaches all of its receptors in an intact form (6, 9, 16, 17, 43, 55, 56, 63). Therefore, we hypothesize that it might have a local action in the ileum. The objectives of this study were to determine whether GLP-1 acted on the canine ileum, a site at which it is released in the canine intestine, and to determine the site and nature of any such actions.


    METHODS
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

Animals. Random source dogs were studied. Animals of both sexes were used if they were in good health and had been treated in our animal facility for parasites. They were anesthetized with 40 mg/kg pentobarbital sodium and maintained at a level of anesthesia in which they did not respond to pain and had no eye-blink reaction to touching the cornea. They were respired artificially throughout the experiment. They were euthanized after surgery and completion of the experiment with intraveous hypertonic KCl. These procedures were approved by the McMaster University Animal Care Committee.

Preparation of isolated segments. This has previously been described in detail (13, 14, 32-35, 38, 45, 69) and is summarized briefly. The abdomen was opened with a midline incision, and the ileum was brought to the exterior. A segment of 10-15 cm was isolated completely from the body by cannulating a terminal artery and vein, perfusing the artery at 2.7 ml/min with physiological saline, collecting the venous effluent, cutting all connection by mesentery, nerves, and vasculature to the body, and separating the segment from the intestine by double ties at each end. At the distal end, a drainage cannula was inserted into the lumen through a stab wound and tied in place with a purse-string suture. Luminal drainage was by gravity. Two strain gauges were sewed to the serosa to record circular muscle contraction, one 2-3 cm from the proximal and the other 2-3 cm from the distal end. Two pairs of 1-cm-long silver stimulating electrodes were inserted subserosally oriented in the circumferential axis. Each pair was 0.5-1 cm distal to the strain gauges to initiate ascending excitation. The exposed ileal segment was wrapped in paraffin-soaked gauze and warmed with a lamp. The animal was warmed with a heater in the operating table.

Close intra-arterial perfusion. The techniques for perfusing the gastric corpus, antrum, pylorus, and duodenum have been previously described (2, 25-27, 29-31). Briefly, in animals anesthetized as described above, an artery close to the organ was selected and cannulated with a small cannula containing heparinized physiological solution. The area perfused was delineated with a perfusion of physiological solution, a strain gauge was attached to record circular muscle contractions, and electrodes pairs were inserted 0.5-1 cm below in cirumferential orientation.

Protocols. In all cases, a recovery period of 30 min was followed by perfusion of increasing concentrations of acetylcholine until a maximum response was attained. Other contractions were evaluated in terms of the percent maximal response to acetylcholine. Acetylcholine was also infused intermittently and after completion of the experiment to ascertain that contractility remained unimpaired. If the response to a maximal dose was decreased to <80%, the experiment was discarded. After a further rest period of 10-15 min, the tissues were stimulated with electrical field stimulation (EFS) of the electrodes distal to the strain gauges (3 pulses/s, 40 V/cm, 0.5-ms duration). In isolated segments, EFS was continued for 6 min, with a change in the polarity of the stimulating electrodes after 3 min. The two sets of electrodes (below the proximal and distal strain gauges) were each stimulated alternately for 6 min throughout the experiment, and data from both electrode sites were combined to study the time of effects of GLP-1. EFS was carried out initially until stable responses were obtained. GLP-1 infusions in physiological solution, by way of a T tube in the intra-arterial cannula, were found in preliminary experiments to have a delayed the onset of action, partly due to the dead space in the perfusion tubing but mostly due to the inherent action of the agent. In experiments with close intra-arterial infusion, actions of GLP-1 were studied on responses to EFS as described above or on responses to repetitive infusions of a submaximal dose of acetylcholine (35). The physiological solution contained (in mM) 115.5 NaCl, 21.9 NaHCO3, 4.6 KCl, 1.16 MgSO4 · 7H2O, 1.16 NaH2PO4 · H2O, 2.5 CaCl2, and 11.1 glucose, maintained at 37°C and bubbled with 95% O2-5% CO2.

Data analysis. Records of the second minute of each recording at a given polarity of stimulation were analyzed (during the initial minute, contractile activities were unstable). Tonic tension data were analyzed as area under the contraction curve as previously described (13). Phasic tension increments were analyzed separately from tonic increments by summing each contraction during the second minute and averaging the value. To obtain data on the duration of action of GLP-1, responses both from proximal and distal electrodes and at both polarities of stimulation were combined. NG-nitro-L-arginine (L-NNA) infusion increased tonic and phasic activity. The effect of L-NNA on responses to GLP-1 was studied by evaluating the percent decrease in the increment of activity caused by EFS after L-NNA vs. that in the increment before L-NNA.

Statistical analysis. Data were usually analyzed by paired comparisons with Dunnett's correction when multiple comparisons were made (Prism 3 software). When the effects of L-NNA on responses to GLP-1 were assessed, the comparison was between the percent inhibition of responses to the same concentration of GLP-1 before L-NNA compared with responses after L-NNA.

Drugs and reagents. GLP-1 and exendin-(939) amide were obtained from Bachem Bioscience (Philadelphia, PA). C capsaicin and the capsaicin receptor antibody were from Calbiochem-Novabiochem (San Diego, CA). Other drugs and chemicals were from Sigma (St. Louis, MO).


    RESULTS
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

In vivo GLP-1 caused marked inhibition of gastric emptying in dogs fed a saline meal. This resulted from increased pyloric tone and inhibition of propulsive antral contractions (4). Therefore, we initially evaluated the effects of intra-arterial infusion of GLP-1 (0.1-100 ng) into the antral and pyloric regions of anesthetized dogs at rest and during stimulation of enteric and vagal nerves as previously described (2, 26). There were no effects (data from 6 experiments not shown). We also infused GLP-1 intravenously while activating enteric nerves, again without effect. These results shifted our focus to the ileum.

When GLP-1 (10-11-10-9 M) was infused intra-arterially into the ileum (n = 6) during stimulation from serosal electrodes placed 0.5-1 cm distal to the strain gauge over the perfused site (to elicit the ascending excitatory reflex), there was persistent inhibition of the phasic activity elicited by EFS (Fig. 1B). A similar GLP-1 infusion had no significant effect on responses to acetylcholine given intra-arterially every 2 min. These studies (n = 4) also showed that, under resting conditions, GLP-1 perfusions were without significant contractile effect (Fig. 1A). We observed that recovery of phasic activity in response to EFS after intra-arterial infusions of GLP-1 was delayed for long periods.


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 1.   Top: representative tracing showing that intra-arterial glucagon-like peptide (GLP)-1 (10-10 M) had no consistent effect on the amplitude of responses to ACh (0.5 µg) given every 2 min. Fl refers to a control flush of equal volume to the ACh injection (n = 4). Bottom: representative trace showing that intra-arterial GLP-1 (10-10 M) nearly abolished the responses to electrical field stimulation (EFS; at 40 V/cm, 0.5 ms, 3 pulses/s). Polarity was reversed to ensure that electrode polarization played no role. Fl refers to a control flush of equal volume to the GLP-1 injection (n = 5). The vertical bar represents 100% of the maximal response to ACh in this tissue for the top trace and 25% of the maximal response to ACh in the tissue in the bottom trace.

To understand the mechanisms involved, we used isolated arterially perfused ileal segments instrumented with two strain gauges, each with a distal pair of serosal electrodes, stimulated alternately as described in METHODS. Infusion of GLP-1 inhibited responses to EFS of these electrodes applied alternately to the proximal and distal pair. Figure 2 shows an example of the concentration-dependent (10-8-3 × 10-7 M) effects of GLP-1 infusions. Infusions were carried out for 8 min and studied for at least 6 min after infusions were stopped on responses to EFS. Maximum inhibition was obtained with 10-7 M GLP-1 (10-9 M had no consistent effect). Figure 3 summarizes experiments of this type, demonstrating that GLP-1 primarily inhibited phasic but not tonic responses to EFS.


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 2.   Excerpts from a representative experiment showing the effect of increasing concentrations of GLP-1 on phasic and tonic activity from EFS in isolated ileal segments. GLP-1 was given for 8 min, and the recordings were made 6 min later (14 min after the administration of GLP-1 was begun). Tracing is marked with the baseline to show how tonic and phasic activities were determined. One-minute intervals were marked as well. Arrows up indicate the onset of EFS. Arrows down indicate the reversal of polarity of stimulation. Double line indicates the end of EFS stimulation. The distance between the second and third tracings correspond to 100% of the maximal ACh response.



View larger version (30K):
[in this window]
[in a new window]
 
Fig. 3.   A: summary of the analysis of 4 phasic activities in experiments with increasing concentrations of GLP-1. All values were significantly different from controls, and the changes at 10-7 and 3 × 10-7 M were significantly different from that at 10-8 M but not from one another. We used 10-7 M as the maximal concentration (n = 7). B: summary of the same experiments showing that there were no significant changes in tonic activity from these concentrations of GLP-1.

To define the duration of action of GLP-1, experiments were carried out using a concentration of 10-7 M for 8 min. EFS was carried out alternately at both proximal and distal strain gauges, and the effects were assembled (Fig. 4). The inhibition of phasic activity extended for >22 min (>15 min after perfusion was stopped), whereas there were no consistent effects on tonic contractile activity.


View larger version (27K):
[in this window]
[in a new window]
 
Fig. 4.   A: time course of the action of GLP-1 (10-7 M), perfused for 8 min. The data were assembled from recordings from the proximal and distal sites in the same segment. Note that the onset of the response was at ~7 min after the infusion and persisted until ~25 min from the onset of perfusion (n = 5-7). B: data from the same experiments as in A showing that there was no consistent effect of GLP-1 on tonic actities.

Exendin-(939) amide (3 × 10-8 M) infused for 14 min before and during infusion of either 3 × 10-8 or 10-7 M GLP-1 had no ability to interfere with the inhibitory action of GLP-1 on phasic activity in response to EFS (Fig. 5). GLP-1 infused after exendin-(939) had no effect on tone as usual (not shown). Exendin-(939) itself had no effects on phasic responses to EFS (Fig. 6) or tonic responses (not shown).


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 5.   Effect of 3 × 10-8 M GLP-1 after and during infusion of exendin-(939). Note that the inhibitory effects for GLP-1, at a submaximal concentration, were not reduced by exendin-(939). As usual, there were no changes in the tonic activity (not shown; n = 5).



View larger version (14K):
[in this window]
[in a new window]
 
Fig. 6.   Lack of significant effect of 3 × 10-8 M exendin-(939) on phasic activity in response to EFS. There was also no effect on the tonic response to EFS (n = 3).

When TTX (10-20 µg) was infused and responses to EFS were abolished, persistent phasic and tonic activity ensued as previously described (12, 35). GLP-1 had no effect on this activity in concentrations through 3 × 10-7 M (data not shown), indicating that it had no effect on myogenic activity, consistent with its lack of inhibitory effect on responses to intra-arterial acetylcholine. Perfusion of L-NNA (10-4 M) also induced persistent tonic and phasic activity, but responses to excitatory stimulation of proximal enteric nerves were preserved, as previously described (12). GLP-1 had a reduced inhibitory effect on these responses, suggesting that nitric oxide release mediated its effects in part (Fig. 7), and the normalized results were significantly less reduced than in the same tissues perfused with GLP-1 before L-NNA (P < 0.03).


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 7.   Summarized effects of GLP-1 on phasic and tonic activities in response to EFS after NG-nitro-L-arginine (L-NNA) (10-4 M) infused for 10 min. L-NNA produced ongoing phasic and tonic activity on which responses to EFS were superimposed. The EFS-initiated activity and the activity to L-NNA were not affected significantly after L-NNA (n = 5).

Capsaicin infused at 10-6 or 3 × 10-6 M had no effects on responses to EFS, but at 10-5 M, it, similar to GLP-1, caused significant and persistent inhibition of phasic but not tonic responses to EFS (Fig. 8). We attempted to achieve desensitization of responses to capsaicin by subsequent infusions of capsaicin after an infusion of 10-5 M, but we were unable to obtain persistent lack of effect to a subsequent infusion; i.e., when the phasic responses recovered sufficiently to test whether GLP-1 could inhibit it, capsaicin was also capable of reducing it. After capsaicin, GLP-1 still causes inhibition of the residual phasic responses to EFS (Fig. 9), but the magnitude appeared to be less (nonsignificantly). There was no effect of GLP-1 on tone after capsaicin (not shown).


View larger version (28K):
[in this window]
[in a new window]
 
Fig. 8.   A: effects of capsaicin (10-5 M) on phasic activity in response to EFS. Note that inhibition was delayed until 19 min after the start of infusion but then persisted until ~37 min after start of infusion (n = 6). B: effects of capsaicin on tonic activity in response to EFS in the same experiments as in A. Note that there was no significant inhibition.



View larger version (19K):
[in this window]
[in a new window]
 
Fig. 9.   Effects of 10-7 M GLP-1 after 10-5 M capsaicin. There appeared to be a reduced inhibition in response to GLP-1. However, we were unable to show that capsaicin produced persistent desensitization to its own action and were thus unsure of the significance of this result (n = 4).


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

The main findings of this study are that GLP-1 acts locally in the ileal region of the gastrointestinal tract near its release sites to inhibit activity of the enteric nervous system initiated by local activation of the ascending excitatory peristaltic reflex. Under the conditions of our experiments, using an isolated-perfused ileal segment, no extrinsic neural or hormonal influences are involved. GLP-1 causes concentration-dependent persistent inhibition of reflex neural activity, abolished by TTX, reduced by L-NNA, and without any effect on responses to exogenous acetylcholine.

The most surprising and interesting finding was that these effects of GLP-1 were unaffected by prior infusion of exendin-(939) amide, an antagonist of the actions of GLP-1 at the known receptor (7, 10, 15, 18, 39, 52, 72). This receptor mediates most of the known actions of GLP-1, e.g., actions to enhance pancreatic beta -cell growth and release insulin (22, 23, 40, 46, 50, 51, 60, 62), inhibition of gastric emptying, secretion, and intestinal motility (37, 38, 44, 59, 66, 67), central actions on the dorsal vagal nucleus and other central nervous system sites (58, 65). In the current literature, there is only one reported action of GLP-1 that was exendin-(939) insensitive, the activation of hepatic vagal afferent nerves by intraportal infusion of GLP-1 or exendin-4 (54). Thus our data as well as those of Nishizawa et al. (54) suggest that a neural receptor class for the action of GLP-1 may exist. One caveat is that we did not demonstrate that our exendin-(939) was bioactive. In anesthetized animals, there is no readily available test of bioactivity. Thus, although three different batches from the supplier, Bachem, behaved the same in our experiments, it is possible that they were not bioactive. Another caveat is that we did not go to higher concentrations of exendin-(939) because of the very high costs that would have resulted from perfusion before and during the exposure to GLP-1 in multiple experiments. However, we believe that our concentrations were sufficient, at least, to affect the actions of GLP-1 based on reports in the literature (e.g., Ref. 54).

Interestingly, the action of GLP-1, persistent inhibition of phasic activity, was mimicked by capsaicin in a concentration-dependent manner. Capsaicin may have reduced the inhibitory action of subsequent GLP-1, but it clearly did not abolish it, and the change was not significant. This was probably because under our conditions, we were unable to demonstrate persistent desensitization of responses to capsaicin; i.e., when the phasic responses to EFS recovered after capsaicin enough to test the inhibitory effects of GLP-1, the inhibitory response to capsaicin had also recovered. Thus the interpretation of these results must be restrained. Suggestive evidence was that some L cells containing GLP-1 were near sites of immunoreactivity to the capsaicin receptor, presumably on sensory nerves (unpublished observations).

The site of action of GLP-1 released from ileal L cells is unclear, because the peptide is rapidly degraded by a peptidase located in the intestine and on endothelial cells (1, 6, 9, 16, 17, 43). Whether or not GLP-1 released at this site should be considered as having a hormonelike action under physiological conditions is unclear. It may function as a paracrine agent. Thus it is possible that a local site of action near the L cell, where GLP-1 would be present in higher concentrations before degradation, may participate in the physiological role of GLP-1 and may do so by activation of a unique GLP-1 receptor. Clearly, further study is required to evaluate it importance. In this connection, the possibility that the action is on sensory nerves, because it appears that all GLP-1 actions on gastrointestinal motor function operate through neural connections and are not local to the sites of the response, such as the stomach and small intestine, needs to be considered.


    ACKNOWLEDGEMENTS

We acknowledge the valuable technical assistance of C. Gill and Z. Woskowska.


    FOOTNOTES

This research was supported, in part, by the Medical Research Council of Canada and by the Father Sean O'Sullivan Research Fund.

Address for reprint requests and other correspondence: E. E. Daniel, Dept. of Pharmacology, Univ. of Alberta, 9-70 Medical Sciences Bldg., Edmonton, AB, Canada T6G 2H7 (E-mail: edaniel{at}ualberta.ca).

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

May 15, 2002;10.1152/ajpgi.00110.2002

Received 20 March 2002; accepted in final form 8 May 2002.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

1.   Ahren, B, Holst JJ, Martensson H, and Balkan B. Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. Eur J Pharmacol 404: 239-245, 2000[ISI][Medline].

2.   Allescher, HD, Daniel EE, Dent J, Fox JET, and Kostolanska F. Extrinsic and intrinsic neural control of pyloric sphincter pressure in the dog. J Physiol 401: 17-38, 1988[Abstract].

3.   Anini Fu-Cheng, X, Cuber JC, Kervran A, Chariot J, and Roz CY. Comparison of the postprandial release of peptide YY and proglucagon-derived peptides in the rat. Pflügers Arch 438: 299-306, 1999[ISI][Medline].

4.   Anvari, M, Craig A, Paterson A, Daniel EE, and McDonald T. Effects of GLP-1 on gastric emptying, antropyloric motility and transpyloric flow in response to a non-nutrient liquid. Dig Dis Sci 43: 1133-1140, 1998[ISI][Medline].

5.   Baggio, L, Kieffer TJ, and Drucker DJ. Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, regulates fasting glycemia and nonenteral glucose clearance in mice. Endocrinology 141: 3703-3709, 2000[Abstract/Free Full Text].

6.   Balkan, B, Kwasnik L, Miserendino R, Holst JJ, and Li X. Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (736 amide) concentrations and improves oral glucose tolerance in obese Zucker rats. Diabetologia 42: 1324-1331, 1999[ISI][Medline].

7.   Blazquez, E, Alvarez E, Navarro M, Roncero I, Rodriguez-Fonseca F, Chowen JA, and Zueco JA. Glucagon-like peptide-1 (7-36) amide as a novel neuropeptide. Mol Neurobiol 18: 157-173, 1998[ISI][Medline].

8.   Bottcher, G, Alumets J, Hakanson R, and Sundler F. Co-existence of glicentin and peptide YY in colorectal L-cells in cat and man. An electron microscopic study. Regul Pept 13: 283-291, 1986[ISI][Medline].

9.   Burcelin, R, Dolci W, and Thorens H. Long-lasting antidiabetic effect of a dipeptidyl peptidase IV-resistant analog of glucagon-like peptide-1. Metabolism 48: 252-258, 1999[ISI][Medline].

10.   Campos, RV, Lee YC, and Drucker DJ. Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse. Endocrinology 134: 2156-2164, 1994[Abstract].

11.   D'Alessio, DA, Vogel R, Prigeon R, Laschansky E, Koerker D, Eng J, and Ensinck JW. Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons. J Clin Invest 97: 133-138, 1996[Abstract/Free Full Text].

12.   Daniel, EE, Haugh C, Woskowska Z, Cipris S, Jury J, and Fox-Threlkeld JET Role of NO-related inhibition in intestinal function: Relation to vasoactive intestinal polypeptide (VIP). Am J Physiol Gastrointest Liver Physiol 266: G31-G39, 1994[Abstract/Free Full Text].

13.   Daniel, EE, and Kostolanska F. Functional studies of nerve projections in the canine intestine. Can J Physiol Pharmacol 67: 1074-1085, 1989[ISI][Medline].

14.   Daniel, EE, Parrish MB, Watson EG, Fox-Threlkeld JET, Regoli D, and Rainsford KD. The tackykinin receptors inducing contractile responses of canine ileum circular muscle. Am J Physiol Gastrointest Liver Physiol 268: G161-G170, 1995[Abstract/Free Full Text].

15.   Davis, HR, Jr, Mullins DE, Pines JM, Hoos LM, France CF, Compton DS, Graziano MP, Sybertz EJ, Strader CD, and Van Heek M. Effect of chronic central administration of glucagon-like peptide-1 (7-36) amide on food consumption and body weight in normal and obese rats. Obesity Res 6: 147-156, 1998[Abstract].

16.   Deacon, CF, Hughes TE, and Holst JJ. Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig. Diabetes 47: 764-769, 1998[Abstract].

17.   Deacon, CF, Knudsen LB, Madsen K, Wiberg FC, Jacobsen O, and Holst JJ. Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity. Diabetologia 41: 271-278, 1998[ISI][Medline].

18.  Dillon JS, Tanizawa Y, Wheeler MB, Leng XH, Ligon BB, Rabin DU, Yoo-Warren H, Permutt MA, and Boyd AE. Cloning and functional expression of the human glucagon-like peptide-1 (GLP-1) receptor. Endocrinology 133: 1907-1910.

19.   Dunphy, JL, Taylor RG, and Fuller PJ. Tissue distribution of rat glucagon receptor and GLP-1 receptor gene expression. Mol Cell Endocrinol 141: 179-186, 1998[ISI][Medline].

20.   Drucker, DJ. Minireview: the glucagon-like peptides. Endocrinology 142: 521-527, 2001[Abstract/Free Full Text].

21.   Drucker, DJ, Lovshin J, Baggio L, Nian M, Adatia F, Boushey RP, Liu Y, Saleh J, Yusta B, and Scrocchi L. New developments in the biology of the glucagon-like peptides GLP-1 and GLP-2. Ann NY Acad Sci 921: 226-232, 2000[Abstract/Free Full Text].

22.   Edwards, CM, Todd JF, Mahmoudi M, Wang Z, Wang RM, Ghatei MA, and Bloom SR. Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. Diabetes 48: 86-93, 1999[Abstract].

23.   Edwards, LC, Chisholm C, and Greenberg GR. Glucagon-like peptide-1-(7-36) amide and peptide YY mediate intraduodenal fat-induced inhibition of acid secretion in dogs. Endocrinology 139: 189-194, 1998[Abstract/Free Full Text].

24.   Eissele, R, Goke R, Willemer S, Harthus HP, Vermeer H, Arnold R, and Goke B. Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. Eur J Clin Invest 22: 283-291, 1992[ISI][Medline].

25.   Fox, JET, and Daniel EE. Substance P: a potent inhibitor of the canine small intestine in vivo. Am J Physiol Gastrointest Liver Physiol 250: G21-G27, 1986[Abstract/Free Full Text].

26.   Fox, JET, and Daniel EE. Exogenous opiates: their local mechanisms of action in the canine small intestine and stomach. Am J Physiol Gastrointest Liver Physiol 253: G179-G188, 1987[Abstract/Free Full Text].

27.   Fox, JET, and Daniel EE. Activation of endogenous excitatory opiate pathways in the canine small intestine by field stimulation and motilin. Am J Physiol Gastrointest Liver Physiol 253: G189-G194, 1987[Abstract/Free Full Text].

28.   Fox, JET, Daniel EE, Jury J, Fox AE, and Collins SM. Sites and mechanisms of action of neuropeptides on canine gastric motility differ in vivo and in vitro. Life Sci 33: 817-825, 1983[ISI][Medline].

29.   Fox, JET, Daniel EE, Jury J, and Robotham H. The mechanisms of motilin excitation of the canine small intestine. Life Sci 34: 1001-1006, 1984[ISI][Medline].

30.   Fox, JET, Kostolanska F, Daniel EE, Allescher HD, and Hanke T. Mechanisms of excitatory actions of neurotensin on canine small intestinal circular muscle in vivo and in vitro. Can J Physiol Pharmacol 65: 2254-2259, 1987[ISI][Medline].

31.   Fox-Threlkeld, JET, Daniel EE, Christinck F, Hruby VJ, Cipris S, and Woskowska Z. Identification of mechanisms and sites of actions of mu and delta opioid receptor activation in the canine intestine. J Pharmacol Exp Ther 268: 689-700, 1994[Abstract].

32.   Fox-Threlkeld, JET, Manaka H, Manaka Y, Cipris S, and Daniel EE. Stimulation of circular muscle motility of the isolated perfused canine ileum: relationship to VIP output. Peptides 12: 1039-1045, 1991[ISI][Medline].

33.   Fox-Threlkeld, JET, McDonald TJ, Cipris S, Woskowska Z, and Daniel EE. Galanin inhibition of VIP release and circular muscle motility in the isolated perfused canine ileum. Gastroenterology 101: 1471-1476, 1991[ISI][Medline].

34.   Fox-Threlkeld, JET, McDonald TJ, Woskowska Z, and Daniel EE. Pituitary adenylate cyclase-activating peptide as a neurotransmitter in the canine ileal circular muscle. J Pharmacol Exp Ther 290: 66-75, 1999[Abstract/Free Full Text].

35.   Fox-Threlkeld, JET, Woskowska Z, and Daniel EE. Sites of nitric oxide (NO) actions in control of circular muscle motility of the perfused isolated canine ileum. Can J Physiol Pharmacol 75: 1340-1349, 1997[ISI][Medline].

36.   Fujimiya, M, and Inui A. Peptidergic regulation of gastrointestinal motility in rodents. Peptides 21: 1565-1582, 2000[ISI][Medline].

37.   Fung, LC, Chisholm C, and Greenberg GR. Glucagon-like peptide-1-(7-36) amide and peptide YY mediate intraduodenal fat-induced inhibition of acid secretion in dogs. Endocrinology 139: 189-194, 1998[Abstract/Free Full Text].

38.   Giralt, M, and Vergara P. Glucagonlike peptide-1 (GLP-1) participation in ileal brake induced by intraluminal peptones in rat. Dig Dis Sci 44: 322-329, 1999[ISI][Medline].

39.   Gulpinar, MA, Bozkurt A, Coskun T, Ulusoy NB, and Yegen BC. Glucagon-like peptide (GLP-1) is involved in the central modulation of fecal output in rats. Am J Physiol Gastrointest Liver Physiol 278: G924-G929, 2000[Abstract/Free Full Text].

40.   Hallbrink, M, Holmqvist T, Olsson M, Ostenson CG, Efendic S, and Langel U. Different domains in the third intracellular loop of the GLP-1 receptor are responsible for Galpha (s) and Galpha (i)/Galpha (o) activation. Biochim Biophys Acta 1546: 79-86, 2001[ISI][Medline].

41.   Hansen, L, Hatmann B, Bisgaard T, Mineo H, Jorgensen PN, and Holst JJ. Somatostatin restrains the secretion of glucagon-like peptide-1 and -2 from isolated perfused porcine ileum. Am J Physiol Endocrinol Metab 278: E1010-E1018, 2000[Abstract/Free Full Text].

42.   Holst, JJ. Glucagonlike peptide 1: a newly discovered gastrointestinal hormone. Gastroenterology 107: 1848-1855, 1994[ISI][Medline].

43.   Holst, JJ, and Deacon CF. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes 47: 1663-1670, 1998[Abstract].

44.   Ímeryuz, N, Yegen BC, Bozkurt A, Coskun T, Villanueva-Penacarrillo ML, and Ulusoy NB. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am J Physiol Gastrointest Liver Physiol 273: G920-G927, 1997[Abstract/Free Full Text].

45.   Manaka, H, Manaka Y, Kostolanska F, Fox JET, and Daniel EE. Release of VIP and substance P from isolated perfused canine ileum. Am J Physiol Gastrointest Liver Physiol 257: G182-G190, 1989[Abstract/Free Full Text].

46.   Montrose-Rafizadeh, C, Yang H, Wang Y, Roth J, Montrose MH, and Adams LG. Novel signal transduction and peptide specificity of glucagon-like peptide receptor in 3T3-L1 adipocytes. J Cell Physiol 172: 275-283, 1997[ISI][Medline].

47.   Naslund, E, Barkeling B, King N, Gutniak M, Blundell JE, Holst JJ, Rossner S, and Hellstrom PM. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obes Relat Metab Disord 23: 304-311, 1999b[Medline].

48.   Naslund, E, Bogefors J, Skogar S, Gryback P, Jacobsson H, Holst JJ, and Hellstrom PM. GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. Am J Physiol Regul Integr Comp Physiol 277: R910-R916, 1999[Abstract/Free Full Text].

49.   Nauck, MA. Glucagon-like peptide 1 (GLP-1): a potent gut hormone with a possible therapeutic perspective. Acta Diabetol 35: 117-129, 1998[ISI][Medline].

50.   Nauck, MA, Holst JJ, Willms B, and Schmiegel WH. Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes. Exp Clin Endocrinol Diabetes 105: 87-95, 1997.

51.   Nauck, MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R, and Schmiegel WH. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol Endocrinol Metab 273: E981-E988, 1997[Abstract/Free Full Text].

52.   Navarro, M, Rodriquez de Fonseca F, Alvarez E, Chowen JA, Zueco JA, Gomez R, Eng J, and Blazquez E. Colocalization of glucagon-like peptide-1 (GLP-1) receptors, glucose transporter GLUT-2, and glucokinase mRNAs in rat hypothalamic cells: evidence for a role of GLP-1 receptor agonists as an inhibitory signal for food and water intake. J Neurochem 67: 1982-1991, 1996[ISI][Medline].

53.   Nilsson, O, Bilchik AJ, Goldenring JR, Ballantyne GH, Adrian TE, and Modlin IM. Distribution and immunocytochemical colocalization of peptide YY and enteroglucagon in endocrine cells of the rabbit colon. Endocrinology 129: 139-148, 1991[Abstract].

54.   Nishizawa, M, Nakabayashi H, Kawai K, Ito T, Kawakami S, Nakagawa A, Niijima A, and Uchida K. The hepatic vagal reception of intraportal GLP-1 is via receptor different from the pancreatic GLP-1 receptor. J Auton Nerv Syst 80: 14-21, 2000[ISI][Medline].

55.   Pauly, RP, Demuth HU, Rosche F, Schmidt J, White HA, Lynn F, McIntosh CH, and Pederson RA. Improved glucose tolerance in rats treated with the dipeptidyl peptidase IV (CD26) inhibitor Ile-thiazolidide. Metabolism 48: 385-389, 1999[ISI][Medline].

56.   Pederson, RA, White HA, Schlenzig D, Pauly RP, McIntosh CH, and Demuth HU. Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide. Diabetes 47: 1253-1258, 1998[Abstract].

57.   Rayner, CK, Park HS, Wishart JM, Kong M, Doran SM, and Horowitz M. Effects of intraduodenal glucose and fructose on antropyloric motility and appetite in healthy humans. Am J Physiol Regul Integr Comp Physiol 278: R360-R366, 2000[Abstract/Free Full Text].

58.   Rodriquez de Fonseca, F, Navarro M, Alvarez E, Roncero I, Chowen JA, Maestre O, Gomez R, Munoz RM, Eng J, and Blazquez EF. Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats. Metabolism 49: 709-717, 2000[ISI][Medline].

59.   Schirra, J, Houck P, Wank U, Arnold R, Goke B, and Katschinski M. Effects of glucagon-like peptide-1(7-36)amide on antro-pyloro-duodenal motility in the interdigestive state and with duodenal lipid perfusion in humans. Gut 46: 622-631, 2000[Abstract/Free Full Text].

60.   Schirra, J, Katschinski M, Weidmann C, Schafer T, Wank U, Arnold R, and Goke B. Gastric emptying and release of incretin hormones after glucose ingestion in humans. J Clin Invest 97: 92-103, 1996[Abstract/Free Full Text].

61.   Schirra, J, Leicht P, Hildebrand P, Beglinger C, Arnold R, Goke B, and Katschinski M. Mechanisms of the antidiabetic action of subcutaneous glucagon-like peptide-1(7-36)amide in non-insulin dependent diabetes mellitus. J Endocrinol 156: 177-186, 1998[Abstract/Free Full Text].

62.   Scrocchi, LA, Marshall BA, Cook SM, Brubaker PL, and Drucker DJ. Identification of glucagon-like peptide 1 (GLP-1) actions essential for glucose homeostasis in mice with disruption of GLP-1 receptor signaling. Diabetes 47: 632-639, 1998[Abstract].

63.   Siegel, EG, Gallwitz B, Scharf G, Mentlein R, Morys-Wortmann C, Folsch UR, Schrezenmeir J, Drescher K, and Schmidt WE. Biological activity of GLP-1-analogues with N-terminal modifications. Regul Pept 79: 93-102, 1999[ISI][Medline].

64.   Siegel, EG, Scharf G, Gallwitz B, Mentlein R, Morys-Wortmann C, Folsch UR, and Schmidt WE. Comparison of the effect of native glucagon-like peptide 1 and dipeptidyl peptidase IV-resistant analogues on insulin release from rat pancreatic islets. Eur J Clin Invest 29: 610-614, 1999[ISI][Medline].

65.   Szayna, M, Doyle ME, Betkey JA, Holloway HW, Spencer RG, Greig NH, and Egan JM. Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology 141: 1936-1941, 2000[Abstract/Free Full Text].

66.   Tolessa, T, Gutniak M, Holst JJ, Efendic S, and Hellstrom PM. Glucagon-like peptide-1 retards gastric emptying and small bowel transit in the rat: effect mediated through central or enteric nervous mechanisms. Dig Dis Sci 43: 2284-2290, 1998[ISI][Medline].

67.   Tolessa, T, Gutniak M, Holst JJ, Efendic S, and Hellstrom PM. Inhibitory effect of glucagon-like peptide-1 on small bowel motility. Fasting but not fed motility inhibited via nitric oxide independently of insulin and somatostatin. J Clin Invest 102: 764-774, 1998[Abstract/Free Full Text].

68.   Vaillant, CR, and Lund PK. Distribution of glucagon-like peptide I in canine and feline pancreas and gastrointestinal tract. J Histochem Cytochem 34: 1117-1121, 1986[Abstract].

69.   Vergara, P, Woskowska Z, Cipris S, Fox-Threlkeld JET, and Daniel EE. Mechanisms of action of cholecystokinin in the canine gastrointestinal tract: role of vasoactive intestinal peptide and nitric oxide. J Pharmacol Exp Ther 279: 306-316, 1996[Abstract].

70.   Wettergren, A, Wojdemann M, and Holst JJ. Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow. Am J Physiol Gastrointest Liver Physiol 275: G984-G992, 1998[Abstract/Free Full Text].

71.   Wishart, JM, Horowitz M, Morris HA, Jones KL, and Nauck MA. Relation between gastric emptying of glucose and plasma concentrations of glucagon-like peptide-1. Peptides 19: 1049-1053, 1998[ISI][Medline].

72.   Yamato, E, Ikegami H, Takekawa K, Fujisawa T, Nakagawa Y, Hamada Y, Ueda H, and Ogihara T. Tissue-specific and glucose-dependent expression of receptor genes for glucagon and glucagon-like peptide-1 (GLP-1). Horm Metab Res 29: 56-59, 1997[ISI][Medline].


Am J Physiol Gastrointest Liver Physiol 283(3):G595-G602
0193-1857/02 $5.00 Copyright © 2002 the American Physiological Society




This Article
Abstract
Full Text (PDF)
All Versions of this Article:
283/3/G595    most recent
00110.2002v1
Alert me when this article is cited
Alert me if a correction is posted
Citation Map
Services
Email this article to a friend
Similar articles in this journal
Similar articles in ISI Web of Science
Similar articles in PubMed
Alert me to new issues of the journal
Download to citation manager
Search for citing articles in:
ISI Web of Science (1)
Google Scholar
Articles by Daniel, E. E.
Articles by McDonald, T. J.
Articles citing this Article
PubMed
PubMed Citation
Articles by Daniel, E. E.
Articles by McDonald, T. J.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online